Fig. 5
Nb-TriTE treatment enhances antitumor efficacy in multiple cancer types. A Schematic representation of the experimental timeline. NOD/SCID mice (n = 5 per group) were subcutaneously implanted with 1 × 106 HepG2-FAP tumor cells on day 0, intravenously injected with human PBMCs at a ratio of 1:10 on day 7, and then treated with the Nb-TriTE or the indicated antibodies (20 μg) by daily intravenous infusion for a total of 6 doses. B Tumor volume growth curves. C Kaplan‒Meier survival curves. D Schematic experimental design of CAFs: PANC1 tumor xenograft studies. E Tumor volumes, F Survival curves of CAFs: PANC1 tumors in NOD/SCID mice treated with the indicated antibodies by daily intravenous infusion (n = 5 per group) G Operational diagram of the animal experiment, H HE staining of brain, I Survival curves of U87 tumors in NOD/SCID mice treated with the indicated antibodies by daily intravenous infusion. J Heatmap showed the expression levels of candidate genes in tumor tissues from Irrelevant ctr-treated mice, Nb-BiTE-treated mice or Nb-TriTE-treated mice. K GO enrichment analysis of genes in tumor tissues from Nb-BiTE-treated versus Nb-TriTE-treated mice. L TPM was used for relative assessment of gene expression levels, such as T cell activation, proliferation and T cell cytotoxicity-associated genes (n = 3 independent biological samples)